<DOC>
	<DOCNO>NCT01984697</DOCNO>
	<brief_summary>This study 37-month safety immunogenicity study conduct boy girl 9 14 year age young woman 16 26 year age . From study , goal establish investigational 2-dose regimen ( 0 , 6 month 0 , 12 month ) study boys girl 9 14 year age generally safe immunogenic , antibody response inferior observe young woman 16 26 year age receive standard 3-dose regimen V503 ( i.e. , population dose regimen use establish V503 efficacy ) .</brief_summary>
	<brief_title>A Phase III Study 2-dose Regimen Multivalent Human Papillomavirus ( HPV ) Vaccine ( V503 ) , Administered 9 14 Year-olds Compared Young Women , 16 26 Years Old ( V503-010 )</brief_title>
	<detailed_description />
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All Participants : Judged good physical health basis medical history , physical examination laboratory result Boys Girls 9 14 Years : Must coitarche plan become sexually active vaccination period Women 16 26 Years : Has never Papanicolaou ( Pap ) test normal Pap test result A lifetime history 0 4 male and/or female sexual partner All Participants : Known allergy vaccine component History severe allergic reaction require medical intervention Thrombocytopenia coagulation disorder Females : participant pregnant expect donate egg day 1 month 7 Currently immunocompromised , diagnosed immunodeficiency Had splenectomy Receiving receive immunosuppressive therapy within last year Received immunoglobulin product bloodderived product within 3 month Received marketed HPV vaccine participate HPV vaccine clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>